Imagen de Portada

Factors Associated With Abdominal Pain in Patients With Active and Quiescent Ulcerative Colitis: A Multicohort Study

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Tom van Gils, Hans Törnblom, Jóhann P. Hreinsson, Börje Jonefjäll, Hans Strid, Magnus Simrén
Formato:	Artículo Open Access
Publicado:	Wiley 2024
Materias:	Alimentary Pharmacology & Therapeutics
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Editorial: Understanding Factors Associated With Abdominal Pain in Ulcerative Colitis—No Surprises But the Usual Suspects Need Greater Attention
por: Weilun Gao, et al.
Publicado: (2024)

Editorial: Can we predict or not predict response to hypnotherapy? That is the question
por: Jenny Lövdahl, et al.
Publicado: (2024)

Letter: A Patient Centric Approach to Tapering Steroids in Steroid Responsive Moderate to Severely Active Ulcerative Colitis
por: Ganesh Bhat, et al.
Publicado: (2026)

Letter: A Patient Centric Approach to Tapering Steroids in Steroid Responsive Moderate to Severely Active Ulcerative Colitis. Authors' Reply
por: Amol N. Patil, et al.
Publicado: (2026)

Editorial: Striving for Equitable Care in Ulcerative Colitis
por: Edward L. Barnes
Publicado: (2025)

Obesity Is Associated With Worsened Outcomes in Patients With Ulcerative Colitis on Advanced Therapies: A Propensity Matched Cohort Study From the U.S.
por: Aakash Desai, et al.
Publicado: (2025)

Letter: Temporal Trends in the Rate of Colectomy in Ulcerative Colitis
por: Richard Pollok
Publicado: (2025)

The Association of Faecal Calprotectin Measurements With Endo‐Histological Remission in Ulcerative Colitis: A Pooled Analysis
por: Laurie‐Rose Dubé, et al.
Publicado: (2026)

Meta‐Analysis: Exclusive Enteral Nutrition in Adults With Ulcerative Colitis
por: Matthew K. W. Chu, et al.
Publicado: (2025)

Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis
por: Antoine Meyer, et al.
Publicado: (2025)

Letter: Thiopurines the Silent Workhorse for Many Patients After a Flare of Ulcerative Colitis. Authors' Reply
por: Ankit Kumar, et al.
Publicado: (2026)

Editorial: Obesity and Outcomes on Advanced Therapy in Ulcerative Colitis—The Fat of the Matter
por: Anish J. Kuriakose Kuzhiyanjal, et al.
Publicado: (2025)

Letter: Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis
por: Zhidong Zhou, et al.
Publicado: (2025)

Letter: Enhancing Predictive Models for Paediatric Ulcerative Colitis—Addressing Socioeconomic, Environmental and Clinical Factors. Authors' Reply
por: Merle Claßen, et al.
Publicado: (2024)

Long‐Term Outcomes of an Infliximab‐First Versus Vedolizumab‐First Treatment Strategy in Biologic‐Naïve Patients With Ulcerative Colitis
por: Austin Haynesworth, et al.
Publicado: (2024)

Editorial: Dual Advanced Therapy in Refractory Ulcerative Colitis—Hope Beyond Monotherapy
por: Ahmed B. Bayoumy, et al.
Publicado: (2025)

Azathioprine or Tofacitinib as Maintenance Therapy in Corticosteroid‐Responsive Acute Severe Ulcerative Colitis
por: Arshdeep Singh, et al.
Publicado: (2025)

Letter: Steroid Tapering in Ulcerative Colitis: The Importance of Disease Severity and Maintenance Therapy
por: Rónán O'Connor, et al.
Publicado: (2026)

Editorial: Evolving Trends in Ulcerative Colitis Management—Insights From the Lothian Cohort
por: Shintaro Akiyama
Publicado: (2025)

Temporal Trends in Medical and Surgical Management of Ulcerative Colitis in England: 2003–2020
por: J. Couch, et al.
Publicado: (2025)

Editorial: The Appendix—A Dead End for Treating Ulcerative Colitis, After All?
por: Johan D. Söderholm
Publicado: (2025)

Clinical Trial: Study to Investigate the Efficacy and Safety of the Alpha‐2‐Delta Ligand PD‐217,014 in Patients With Irritable Bowel Syndrome
por: Lesley A. Houghton, et al.
Publicado: (2025)

Letter: Exclusive Enteral Nutrition in Ulcerative Colitis—The Path Ahead Needs Careful Consideration
por: Sarah Melton, et al.
Publicado: (2025)

Editorial: Real‐World Effectiveness of Mirikizumab in Ulcerative Colitis—A Valuable but Preliminary Glimpse
por: Mark A. Ainsworth, et al.
Publicado: (2025)

Editorial: Obesity and Outcomes on Advanced Therapy in Ulcerative Colitis—The Fat of the Matter: Authors' Reply
por: Aakash Desai, et al.
Publicado: (2025)

Clinical Trial: Long Versus Short Tapering of Steroids in Steroid Responsive Moderate to Severely Active Ulcerative Colitis—A Randomised Controlled Trial
por: Ankit Kumar, et al.
Publicado: (2026)

Letter: Social work and clinical synergy—Optimizing health interventions for elderly DGBI populations: Authors' reply
por: Ami D. Sperber, et al.
Publicado: (2024)

Clinical Trial Design Considerations for Hospitalised Patients With Ulcerative Colitis Flares and Application to Study Hyperbaric Oxygen Therapy in the NIDDK HBOT‐UC Consortium
por: Parambir S. Dulai, et al.
Publicado: (2024)

Effectiveness and Safety of a Second JAK Inhibitor in Ulcerative Colitis: The J2J Multicentre Study
por: Mathilde Osty, et al.
Publicado: (2025)

Editorial: Effectiveness and Safety of Ustekinumab in Ulcerative Colitis—Where We Are Now in Real Life. Authors' Reply
por: María Chaparro, et al.
Publicado: (2024)

Editorial: Real‐World Effectiveness of Mirikizumab in Ulcerative Colitis—A Valuable but Preliminary Glimpse. Authors' Reply
por: Shinichiro Shinzaki, et al.
Publicado: (2025)

Editorial: Ulcerative Colitis Management in the Biologic Era–Data From the English Healthcare Databases. Authors' Reply
por: J. Couch, et al.
Publicado: (2025)

Letter: Clinical Trial Design Considerations for Hospitalised Patients With Ulcerative Colitis Flares and Application to Study Hyperbaric Oxygen Therapy in the NIDDK HBOT ‐ UC Consortium
por: Brian C. Weiner
Publicado: (2025)

Letter : Is Short Tapering of Steroids in Moderate to Severely Active Ulcerative Colitis Really Inferior to a Long Steroid Taper, or Just Underpowered to Reach a Definitive Conclusion?
por: Hariti Saluja, et al.
Publicado: (2026)

Clinical Trial: Association Between Early Disease Clearance and Long‐Term Outcomes—4‐Year Results From the Phase 3 UNIFI Study of Ustekinumab in Ulcerative Colitis
por: Silvio Danese, et al.
Publicado: (2025)

Clinical Trial: Evaluating a Single 1600 mg Tablet Regimen of 5‐Aminosalicylate for Ulcerative Colitis—The EASI Trial
por: Rie Louise Møller Nordestgaard, et al.
Publicado: (2025)

Editorial: Shooting in the Dark—The Problem With Empiric Antispasmodics for Abdominal Pain in Inflammatory Bowel Disease
por: Jane Lim, et al.
Publicado: (2025)

Editorial: Association of Antibiotic Exposure With Microscopic Colitis—Authors' Reply
por: Máté Szilcz, et al.
Publicado: (2025)

The Impact of Antispasmodic Use on Abdominal Pain and Opioid Use in Inflammatory Bowel Disease: A Population‐Based Study
por: Chachrit Khunsriraksakul, et al.
Publicado: (2025)

Efficacy and Safety of Vedolizumab and Tofacitinib ( VETO ) Combination Therapy in Refractory Ulcerative Colitis Unresponsive to Anti‐ TNF and a Second‐Line Advanced Therapy: A Prospective Cohort Nested Within a Randomised Trial
por: Pardhu Bharath Neelam, et al.
Publicado: (2025)